



**BlueCross  
BlueShield**

Federal Employee Program.

## **RECLAST (zoledronic acid)**

### **RATIONALE FOR INCLUSION IN PA PROGRAM**

#### **Background**

Reclast (zoledronic acid) is a bisphosphonate and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered zoledronic acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover (1).

#### **Regulatory Status**

FDA-approved indication: Reclast is indicated for: (1)

- Osteoporosis
- Prevention of osteoporosis
- Paget's disease

#### **Summary**

Reclast (zoledronic acid) is a bisphosphonate and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered zoledronic acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover (1).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Reclast while maintaining optimal therapeutic outcomes.

#### **References**

1. Reclast [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2020.